International Variation in Adherence to Referral Guidelines for Suspected Cancer: a Secondary Analysis of Survey Data
Overview
Authors
Affiliations
Background: Variation in cancer survival persists between comparable nations and appears to be due, in part, to primary care practitioners (PCPs) having different thresholds for acting definitively in response to cancer-related symptoms.
Aim: To explore whether cancer guidelines, and adherence to them, differ between jurisdictions and impacts on PCPs' propensity to take definitive action on cancer-related symptoms.
Design And Setting: A secondary analysis of survey data from six countries (10 jurisdictions) participating in the International Cancer Benchmarking Partnership.
Method: PCPs' responses to five clinical vignettes presenting symptoms and signs of lung (n = 2), colorectal (n = 2), and ovarian cancer (n = 1) were compared with investigation and referral recommendations in cancer guidelines.
Results: Nine jurisdictions had guidelines covering the two colorectal vignettes. For the lung vignettes, although eight jurisdictions had guidelines for the first, the second was covered by a Swedish guideline alone. Only the UK and Denmark had an ovarian cancer guideline. Survey responses of 2795 PCPs (crude response rate: 12%) were analysed. Guideline adherence ranged from 20-82%. UK adherence was lower than other jurisdictions for the lung vignette covered by the guidance (47% versus 58%; P <0.01) but similar (45% versus 46%) or higher (67% versus 38%; P <0.01) for the two colorectal vignettes. PCPs took definitive action least often when a guideline recommended a non-definitive action or made no recommendation. UK PCPs adhered to recommendations for definitive action less than their counterparts (P <0.01). There wasno association between jurisdictional guideline adherence and 1-year survival.
Conclusion: Cancer guideline content is variable between similarly developed nations and poor guideline adherence does not explain differential survival. Guidelines that fail to cover high-risk presentations or that recommend non-definitive action may reduce definitive diagnostic action.
Salehi A, Rezvani A, Fallahi M, Gholamabbas G, Moayedfar M Cancer Rep (Hoboken). 2024; 7(10):e70026.
PMID: 39423347 PMC: 11488750. DOI: 10.1002/cnr2.70026.
Rafiq M, Renzi C, White B, Zakkak N, Nicholson B, Lyratzopoulos G PLoS Med. 2024; 21(7):e1004426.
PMID: 39078806 PMC: 11288431. DOI: 10.1371/journal.pmed.1004426.
Hiscock J, Law R, Brain K, Smits S, Nafees S, Williams N Br J Gen Pract. 2024; 74(745):e544-e551.
PMID: 38806209 PMC: 11257065. DOI: 10.3399/BJGP.2023.0339.
Black G, Janes S, Callister M, Van Os S, Whitaker K, Quaife S Med Decis Making. 2024; 44(2):152-162.
PMID: 38240273 PMC: 10865750. DOI: 10.1177/0272989X231220954.
Aboelkhir H, Elomri A, ElMekkawy T, Kerbache L, Elakkad M, Al-Ansari A Int J Environ Res Public Health. 2022; 19(24).
PMID: 36554837 PMC: 9778793. DOI: 10.3390/ijerph192416952.